- PN: B111523
45x Ab-conjugated beads (S5P10 - human VEGF-C Ab-bead). PN: B111523A. One vial containing 100 µL of anti-human VEGF-C conjugated to AimPlex Bead S5P10.
25x Biotin-detection Ab (human VEGF-C Biotin-dAb). PN: B111523B. One vial containing 100 µL of biotinylated anti-human VEGF-C.
Lyophilized Standard Mix-Human Group 4 Panel A. PN: HG4009A. One vial containing lyophilized recombinant human BDNF, beta-NGF, EGF, FGF basic, OPG, OPN, PDGF-AB and VEGF-C. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
STORAGE: 2-8 C in the dark.
IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
APPLICATION: Optimal antibody pair and antigen standard for assaying human VEGF-C. Can be multiplexed with other analytes in Human Group 4. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Important: Sample types containing low levels of platelets such as platelet-poor plasma are recommended.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 5 pg/mL
LLOQ: < 10 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 4: Negligible
Sample volume: 15 µL/test
Vascular Endothelial Growth Factor C (VEGF-C) is a member of the platelet-derived growth factor/ vascular endothelial growth factor (PDGF/VEGF) family. The main function of VEGF-C is in lymphangiogenesis, where it acts on lymphatic endothelial cells primarily via its receptor VEGFR-3 promoting survival, growth and migration. It was discovered in 1996 as a ligand for the orphan receptor VEGFR-3. It has been shown to be a specific growth factor for lymphatic vessels in a variety of models. VEGF-C can also promote the growth of blood vessels and regulate their permeability. The effect on blood vessels can be mediated via its primary receptor VEGFR-3 or its secondary receptor VEGFR-2. Apart from vascular targets, VEGF-C is also important for neural development and blood pressure regulation. Diseases associated with VEGFC include lymphedema, hereditary and breast carcinoma.
1. Paavonen K, Horelli-Kuitunen N, Chilov D, Kukk E, Pennanen S, Kallioniemi OP, Pajusola K, Olofsson B, Eriksson U, Joukov V, Palotie A, Alitalo K (Mar 1996). "Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively". Circulation 93 (6): 1079–1082. doi:10.1161/01.CIR.93.6.1079. PMID 8653826.
2. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (Jan 1996). "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases". The EMBO Journal 15 (2): 290–298. PMC 449944. PMID 8617204.
3. Oh SJ, Jeltsch MM, Birkenhäger R, McCarthy JE, Weich HA, Christ B, Alitalo K, Wilting J (Aug 1997). "VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane". Developmental Biology 188 (1): 96–109. doi:10.1006/dbio.1997.8639. PMID 9245515.